Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Depreciation & Amortization (CF) (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $72000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 36.84% year-over-year to $72000.0, compared with a TTM value of $375000.0 through Dec 2025, down 5.54%, and an annual FY2025 reading of $375000.0, down 5.54% over the prior year.
  • Depreciation & Amortization (CF) was $72000.0 for Q4 2025 at Catalyst Pharmaceuticals, roughly flat from $72000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $116000.0 in Q2 2025 and bottomed at $31000.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $71050.0, with a median of $76500.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) soared 592.86% in 2021, then plummeted 64.95% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $33000.0 in 2021, then increased by 6.06% to $35000.0 in 2022, then soared by 140.0% to $84000.0 in 2023, then soared by 35.71% to $114000.0 in 2024, then tumbled by 36.84% to $72000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CPRX at $72000.0 in Q4 2025, $72000.0 in Q3 2025, and $116000.0 in Q2 2025.